Refine by
Medical Testing Articles & Analysis
77 news found
STEMart, a US-based provider of comprehensive services for all phases of medical device development, announced the expansion of its service offerings to include the Bacterial Reverse Mutation Test (Ames) service. ...
BySTEMart
STEMart, a US-based provider of comprehensive services for all phases of medical device development, announces the expansion of its medical device testing capabilities and introduces Balloon Catheter Testing Services for the development of safe and effective medical devices. ...
BySTEMart
The previous guidelines for asthma management from NICE recommended FeNO testing alongside other objective tests, such as spirometry and peak flow. ...
STEMart, a US-based provider of comprehensive services for all phases of medical device development, has announced the launch of its new Accelerated Aging Testing Services for medical device manufacturers to ensure the long-term reliability and safety of their products. ...
BySTEMart
Planning brain surgery is a delicate process that requires precision to avoid damaging surrounding brain tissue and to prevent post-surgery complications. Synaptive Medical, a leader in medical technology, is set to enhance this process by evaluating its new software called Modus Plan, at Unity Health Toronto’s St. ...
STEMart, a US-based provider of comprehensive services for all phases of medical device development, proudly announces the launch of its new Transportation and Distribution Simulation Services for the medical device industry. ...
BySTEMart
The new service offerings include medical device safety testing, biocompatibility testing, validation and verification, and reusable medical device testing. ...
This new development has the potential to revolutionize the way oral medications are tested and administered, leading to more precise and effective treatments for a wide range of medical conditions. ...
STEMart, a US-based provider of comprehensive services for all phases of medical device development, announced the launch of its new Force Degradation Services to help pharmaceutical and medical device companies evaluate the stability of their drug candidates and finished products under a variety of stress conditions, ensuring their safety and efficacy throughout ...
BySTEMart
With the continuous development of technology, so does the field of medical aesthetics. At present, HIFU ultrasound face lifting treatment has become one of the most important technical tools in the medical aesthetic field. ...
ViGeneron’s pipeline in gene therapy addresses ophthalmic diseases with high unmet medical need, including two programs in development for undisclosed indications where no approved treatment options are currently available. ...
” Of the multitude of medications available for the more than 17 million child, adolescent, and adult patients in the U.S. living with ADHD, no currently available medications offer a single oral dose that provides patients entire active-day efficacy. This Phase 3 trial is being conducted in an Adult Laboratory Setting (ALS) which has been used extensively ...
This is achieved by developing and providing integrated and standardized workflows for Next Generation Sequencing (NGS) and integrating information from cancer gene testing, pharmacogenetics testing and e-medication, to support medical decision making. ...
Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced an update on the development of its initial insulin pump product. ...
You will no longer have to wait for days for a central diagnostic laboratory to provide critical medical test data regarding your health. This program showcases a range of young diagnostic companies that are poised to launch exciting products and services that will truly change your ...
Adult ADHD prevalence is estimated at approximately 11 million patients (4.4 percent), double the size of the child and adolescent segment combined, however, only an estimated 20 percent receive treatment. Although there is no single medical, physical, or genetic test for ADHD, qualified mental health care professionals and physicians can provide a diagnostic ...
Adult ADHD prevalence is estimated at approximately 11 million patients (4.4 percent), double the size of the child and adolescent segment combined, however, only an estimated 20 percent receive treatment. Although there is no single medical, physical, or genetic test for ADHD, qualified mental health care professionals and physicians can provide a diagnostic ...
With an expert R&D team and a licenced manufacturing facility with a 50 million+ annual thin film capacity, the Firm is an ideal potential partner to produce XPhyto’s oral dissolvable (“ODF”) biosensor products. They are capable of thin film medical product formulation, mixing, coating, and packaging. In addition, the Firm has a portfolio of OTC and ...
(CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report a significant potential market opportunity for its oral dissolvable (“ODF”) biosensor screening tests for oral inflammation. Certain buprenorphine medicines prescribed to treat opioid use disorder (“OUD”) and pain have been recently associated with ...
Blood tests are the cornerstone of routine and preventive care services, as about 70% of medical decisions depend on lab tests for diagnosis or treatment. The challenge is how to get that data into the hands of a telehealth provider without having to schedule additional lab visits and follow-up appointments to discuss the test ...